Clinical studies consistently demonstrate that a single sub-psychomimetic dose of ketamine, an ionotropic glutamatergic NMDAR (N-methyl-D-aspartate receptor) antagonist, produces fast-acting antidepressant responses in patients suffering from major depressive disorder, although the underlying mechanism is unclear1, 2, 3. Depressed patients report the alleviation of major depressive disorder symptoms within two hours of a single, low-dose intravenous infusion of ketamine, with effects lasting up to two weeks1, 2, 3, unlike traditional antidepressants (serotonin re-uptake inhibitors), which take weeks to reach efficacy. This delay is a major drawback to current therapies for major depressive disorder and faster-acting antidepressants are needed, particularly for suicide-risk patients3. The ability of ketamine to produce rapidly acting, long-lasting antidepressant responses in depressed patients provides a unique opportunity to investigate underlying cellular mechanisms. Here we show that ketamine and other NMDAR antagonists produce fast-acting behavioural antidepressant-like effects in mouse models, and that these effects depend on the rapid synthesis of brain-derived neurotrophic factor. We find that the ketamine-mediated blockade of NMDAR at rest deactivates eukaryotic elongation factor 2 (eEF2) kinase (also called CaMKIII), resulting in reduced eEF2 phosphorylation and de-suppression of translation of brain-derived neurotrophic factor. Furthermore, we find that inhibitors of eEF2 kinase induce fast-acting behavioural antidepressant-like effects. Our findings indicate that the regulation of protein synthesis by spontaneous neurotransmission may serve as a viable therapeutic target for the development of fast-acting antidepressants.
At a glance
- A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856–864 (2006) et al.
- Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351–354 (2000) et al.
- Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol. Psychiatry 66, 522–526 (2009) , , &
- Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 63, 349–352 (2008) et al.
- Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Exp. Clin. Psychopharmacol. 5, 107–112 (1997) , &
- Ketamine. Handb. Exp. Pharmacol. 182, 313–333 (2008) &
- Cardiac arrest and resuscitation alters the pharmacokinetics of MK-801 in the rat. Res. Commun. Chem. Pathol. Pharmacol. 73, 181–195 (1991) &
- CSF and plasma pharmacokinetics of the NMDA receptor antagonist CPP after intrathecal, extradural and i.v. administration in anaesthetized pigs. Br. J. Anaesth. 74, 193–200 (1995) , , , &
- Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol. Psychiatry 50, 260–265 (2001) , , , &
- Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc. Natl Acad. Sci. USA 101, 10827–10832 (2004) et al.
- Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311, 864–868 (2006) et al.
- Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol. Psychiatry 63, 642–649 (2008) , , , &
- Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22, 3251–3261 (2002) , , , &
- Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res. 1037, 204–208 (2005) , &
- Brain-derived neurotrophic factor is essential for opiate-induced plasticity of noradrenergic neurons. J. Neurosci. 22, 4153–4162 (2002) et al.
- Different requirements for protein synthesis in acquisition and extinction of spatial preferences and context-evoked fear. J. Neurosci. 21, 5773–5780 (2001) &
- Actinomycin D blocks the reducing effect of dexamethasone on amphetamine and cocaine hypermotility in mice. Gen. Pharmacol. 27, 707–712 (1996) , , , &
- Postsynaptic decoding of neural activity: eEF2 as a biochemical sensor coupling miniature synaptic transmission to local protein synthesis. Neuron 55, 648–661 (2007) , , , &
- NMDA/glutamate mechanism of antidepressant-like action of magnesium in forced swim test in mice. Pharmacol. Biochem. Behav. 88, 158–164 (2007) et al.
- Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nature Neurosci. 10, 411–413 (2007) et al.
- mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959–964 (2010) et al.
- Antidepressive-like effects of rapamycin in animal models: Implications for mTOR inhibition as a new target for treatment of affective disorders. Brain Res. Bull. 76, 469–473 (2008) et al.
- Spontaneous and evoked glutamate release activates two populations of NMDA receptors with limited overlap. J. Neurosci. 28, 10151–10166 (2008) et al.
- NMDA receptor activation by spontaneous glutamatergic neurotransmission. J. Neurophysiol. 101, 2290–2296 (2009) &
- Protein synthesis and neurotrophin-dependent structural plasticity of single dendritic spines. Science 319, 1683–1687 (2008) et al.
- Local presynaptic activity gates homeostatic changes in presynaptic function driven by dendritic BDNF synthesis. Neuron 68, 1143–1158 (2010) et al.
- Postsynaptic GluA1 enables acute retrograde enhancement of presynaptic function to coordinate adaptation to synaptic inactivity. Proc. Natl Acad. Sci. USA 107, 21806–21811 (2010) et al.
- Partitioning the synaptic landscape: distinct microdomains for spontaneous and spike-triggered neurotransmission. Sci. Signal. 2, pe19 (2009) &
- Spontaneous neurotransmission: an independent pathway for neuronal signaling? Physiology (Bethesda) 26, 45–53 (2011) et al.
- A role for MAP kinase signalling in behavioral models of depression and antidepressant treatment. Biol. Psychiatry 61, 661–670 (2007) , , , &
- Depression: A new animal model sensitive to antidepressant treatments. Nature 266, 730–732 (1977) , &
- Elongation factor 2 and fragile X mental retardation protein control the dynamic translation of Arc/Arg3.1 essential for mGluR-LTD. Neuron 59, 70–83 (2008) et al.
- Activity-dependent regulation of synaptic clustering in a hippocampal culture system. Proc. Natl Acad. Sci. USA 96, 12893–12900 (1999) , &
- Supplementary Figures (1.2M)
The file contains Supplementary Figures 1-15 with legends.